CRM
GILD icon

Cramer Rosenthal McGlynn’s Gilead Sciences GILD Stock Holding History

Cramer Rosenthal McGlynn’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-66,530
Closed -$7.08M – 236
2014
Q3 		$7.08M Sell
66,530
-290,085
-81% -$28.4M 0.07% 166
2014
Q2 		$29.6M Buy
356,615
+133,315
+60% +$10.4M 0.24% 117
2014
Q1 		$15.8M Buy
+223,300
New +$17.5M 0.12% 165

Other funds holding GILD

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Cramer Rosenthal McGlynn's GILD Position: Q4 2014 in Review

Cramer Rosenthal McGlynn sold out of Gilead Sciences (GILD) in Q4 2014, closing a stake of 66,530 shares — an estimated $7.08M sold.

Cramer Rosenthal McGlynn first reported a position in GILD in Q1 2014 and held it in 3 quarters. The position peaked at $29.6M in Q2 2014. 1,438 funds tracked by Wall St. Rank hold GILD as of Q4 2014.

  • Cramer Rosenthal McGlynn reported no remaining Gilead Sciences position as of Q4 2014 after selling out during the quarter.
  • Cramer Rosenthal McGlynn sold 66,530 Gilead Sciences shares in Q4 2014, an estimated $7.08M.
  • Cramer Rosenthal McGlynn first reported a position in Gilead Sciences in Q1 2014 and held it in 3 quarters.
  • Cramer Rosenthal McGlynn's Gilead Sciences position peaked at $29.6M in Q2 2014.
  • 1,438 funds tracked by Wall St. Rank held Gilead Sciences as of Q4 2014.

Based on Cramer Rosenthal McGlynn's 13F filing for Q4 2014, filed 13 Feb 2015.